Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44064   clinical trials with a EudraCT protocol, of which   7320   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-004989-25
    Sponsor's Protocol Code Number:INCAGN1876-201
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2017-07-03
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2016-004989-25
    A.3Full title of the trial
    A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies.
    Estudio de fase I/II sobre la seguridad, la tolerabilidad y la eficacia de INCAGN01876 en combinación con inmunoterapias en sujetos con neoplasias malignas avanzadas o metastásicas
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study exploring the safety, tolerability, and efficacy of INCAGN01876 in combination with immune therapies in subjects with advanced or metastatic malignancies.
    Estudio sobre la seguridad, la tolerabilidad y la eficacia de
    INCAGN01876 en combinación con inmunoterapias en sujetos con neoplasias malignas avanzadas o
    metastásicas”
    A.4.1Sponsor's protocol code numberINCAGN1876-201
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT03126110
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorIncyte Biosciences International Sàrl
    B.1.3.4CountrySwitzerland
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportIncyte Biosciences International Sàrl
    B.4.2CountrySwitzerland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationIncyte Biosciences International Sàrl
    B.5.2Functional name of contact pointMedical Information
    B.5.3 Address:
    B.5.3.1Street Address1, route de la Corniche
    B.5.3.2Town/ cityEpalinges
    B.5.3.3Post code1066
    B.5.3.4CountrySwitzerland
    B.5.6E-mailglobalmedinfo@incyte.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code INCAGN01876
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNnot yet availble
    D.3.9.3Other descriptive nameINCAGN01876
    D.3.9.4EV Substance CodeSUB187157
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Yervoy 5 mg/ml concentrate for solution for infusion
    D.2.1.1.2Name of the Marketing Authorisation holderBristol-Myers Squibb Pharma EEIG
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNIPILIMUMAB
    D.3.9.1CAS number 477202-00-9
    D.3.9.4EV Substance CodeSUB29397
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Opdivo 10 mg/mL concentrate for solution for infusion
    D.2.1.1.2Name of the Marketing Authorisation holderBristol-Myers Squibb Pharma EEIG
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNnivolumab
    D.3.9.1CAS number 946414-94-4
    D.3.9.4EV Substance CodeSUB122750
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Phase 1: advanced or metastatic cervical cancer, endometrial cancer, gastric cancer, hepatocellular carcinoma, melanoma (mucosal or cutaneous), Merkel cell carcinoma, mesothelioma, MSI-H colorectal cancer, non–small cell lung cancer, ovarian cancer, squamous cell carcinoma of the head and neck (SCCHN), small cell lung cancer, renal cell carcinoma, triple-negative breast cancer, and urothelial carcinoma (or others).
    Phase 2: advanced or metastatic endometrial cancer, gastric cancer, and SCCHN
    F I: cáncer cuello uterino, endometrio, gástrico ,carcinoma hepatocelular, melanoma (mucosal o cutaneo), carcinoma células Merkel, mesotelioma, cáncer colorrectal, carcinoma pulmón no microcítico , cáncer ovario, carcinoma epidermoide cabeza/cuello , cáncer microcítico pulmón , carcinoma cél renales , cáncer mama triple negativo y carcinoma urotelial avanzados o metastásicos.
    F II: cáncer endometrio, gástrico y CECC avanzados o metastásicos, (tumores alternativos autorizades Monitor médico).
    E.1.1.1Medical condition in easily understood language
    melanoma, mesothelioma, cervical, endometrial, gastric, liver, skin, colorectal, lung, ovarian, head and neck, kidney, breast and bladder cancer
    Melanoma, mesotelioma, cervical, endometrial, gástrico, hepático, cutáneo, colorrectal, pulmonar, ovárico, de cabeza y cuello, de riñón, de mama y de vejiga
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10041067
    E.1.2Term Small cell lung cancer
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10060121
    E.1.2Term Squamous cell carcinoma of head and neck
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10014733
    E.1.2Term Endometrial cancer
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10027407
    E.1.2Term Mesothelioma malignant
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10064467
    E.1.2Term Urothelial carcinoma
    E.1.2System Organ Class 100000017553
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10073071
    E.1.2Term Hepatocellular carcinoma
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10027150
    E.1.2Term Melanoma malignant
    E.1.2System Organ Class 100000018529
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10064025
    E.1.2Term Merkel cell carcinoma
    E.1.2System Organ Class 100000018548
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10017758
    E.1.2Term Gastric cancer
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10008229
    E.1.2Term Cervical cancer
    E.1.2System Organ Class 100000020977
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10061873
    E.1.2Term Non-small cell lung cancer
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 11.0
    E.1.2Level HLT
    E.1.2Classification code 10038408
    E.1.2Term Renal cell carcinomas
    E.1.2System Organ Class 100000005104
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10061451
    E.1.2Term Colorectal cancer
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10075566
    E.1.2Term Triple negative breast cancer
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10033128
    E.1.2Term Ovarian cancer
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    - Phase 1: To evaluate the safety, tolerability, and DLTs of INCAGN01876 in combination with immune therapies and to define the RP2D(s) of INCAGN01876 when given in combination with immune therapies.
    - Phase 2: To evaluate the efficacy of INCAGN01876 when given in combination with immune therapies by assessing ORR per RECIST v1.1.
    Fase I: Evaluar la seguridad, la tolerabilidad y las toxicidades limitantes de la dosis (TLD) de INCAGN01876 en combinación con inmunoterapias y definir la(s) dosis recomendada(s) para la fase II de INCAGN01876 administrado en combinación con inmunoterapias.
    Fase II: Evaluar la eficacia de INCAGN01876 administrado en combinación con inmunoterapias mediante la evaluación de la tasa de respuesta objetiva (TRO) de acuerdo con los criterios RECIST v1.1.
    E.2.2Secondary objectives of the trial
    Phase 1 and Phase 2:
    • To evaluate the efficacy of INCAGN01876 when given in combination with immune therapies by assessing ORR, DOR, DCR, duration of disease control, and PFS per RECIST v1.1 and mRECIST v1.1.
    • To evaluate the efficacy of INCAGN01876 when given in combination with immune therapies with respect to 1-year and 2-year OS.
    • To evaluate the safety and tolerability of INCAGN01876 when given in combination with immune therapies.
    Fases I y II:
    •Evaluar la eficacia de INCAGN01876 administrado en combinación con inmunoterapias mediante la evaluación de la TRO, la duración de la respuesta (DDR), la tasa de control de la enfermedad (TCE),la duración del control de la enfermedad y la supervivencia sin progresión (SSP) de acuerdo con los criterios RECIST v1.1 y los criterios RECIST v 1.1 modificados (mRECIST).
    •Evaluar la eficacia de INCAGN01876 administrado en combinación con inmunoterapias en cuanto a la supervivencia global (SG) a uno y dos años.
    •Evaluar la seguridad y la tolerabilidad de INCAGN01876 administrado en combinación con inmunoterapias.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    • Locally advanced or metastatic disease; locally advanced disease must not be amenable to resection with curative intent.
    • Phase 1: Subjects with advanced or metastatic cervical cancer, endometrial cancer, gastric cancer (including stomach, esophageal, and GEJ), HCC, melanoma (mucosal or cutaneous), Merkel cell carcinoma, mesothelioma, MSI-H CRC, NSCLC, ovarian cancer, SCCHN, SCLC, RCC, TNBC, and urothelial carcinoma (or alternative tumor types with medical monitor approval).
    • Phase 1: Subjects who have disease progression after treatment with available therapies that are known to confer clinical benefit, or who are intolerant to treatment, or who refuse standard treatment. There is no limit to the number of prior treatment regimens.
    • Phase 2: Subjects with advanced or metastatic endometrial cancer, gastric cancer (including stomach, esophageal, and GEJ), and SCCHN.
    − For subjects with endometrial cancer: should have documented MSI status (eg, MSI-H, MSI-low, microsatellite stable), or consent to local institutional MSI testing during the screening period. Note: Should have received only 1 prior chemotherapy regimen for advanced or metastatic disease (not including neoadjuvant and/or adjuvant therapy). Adjuvant regimens given within 6 months of screening would be counted as first-line therapy. Note: Prior therapy should not have included an immune therapy (eg, anti–cytotoxic T-lymphocyte–associated protein 4 [CTLA-4], anti–programmed cell death protein 1 (PD-1), anti–programmed cell death protein ligand 1 (PD-L1), indoleamine 2,3-dioxygenase [IDO] inhibitors, tumor necrosis factor super family (TNFSF) agonists, or other antibodies or drugs specifically targeting T-cell costimulation or checkpoint pathways, etc). Note: May have received prior hormonal and/or biological therapy concurrent with or in addition to prior systemic chemotherapy.
    − For subjects with gastric cancer: adenocarcinoma of the stomach, esophagus, or GEJ. Note: Should have received only 1 prior chemotherapy regimen for advanced or metastatic disease (not including neoadjuvant and/or adjuvant therapy). Adjuvant regimens given within 6 months of screening would be counted as first-line therapy. Note: Prior therapy should not have included an immune therapy (eg, anti–CTLA-4, anti–PD-1, anti–PD-L1, IDO inhibitors, TNFSF agonists, or other antibodies or drugs specifically targeting T-cell costimulation or checkpoint pathways, etc). Note: HER-2/neu status known and subjects with HER2/neu positive tumors should have documented disease progression on or after treatment containing trastuzumab or other HER2/neu-targeted therapy.
    − For subjects with SCCHN: histologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx. Note: Subjects with tumors that are adjacent to or invade major blood vessels, as shown unequivocally by imaging studies are not eligible for participation. Note: Should consent to have tumor evaluated for HPV and Epstein-Barr virus (EBV) status of the tumor (per local institutional testing), or have documentation of HPV or EBV status. Note: Should have received only 1 prior chemotherapy regimen for advanced or metastatic disease (not including neoadjuvant and/or adjuvant therapy). Adjuvant regimens given within 6 months of screening would be counted as first-line therapy. Prior chemotherapy regimen should have been a platinum-containing regimen. Note: Prior therapy should not have included an immune therapy (eg, anti–CTLA-4, anti–PD-1, anti–PD-L1, IDO inhibitors, TNFSF agonists, or other antibodies or drugs specifically targeting T-cell costimulation or checkpoint pathways, etc).
    − For subjects in the biopsy cohort: willingness to undergo pretreatment and on treatment tumor biopsies (core or excisional). Must have cervical cancer, endometrial cancer, gastric cancer (including stomach, esophageal and GEJ), HCC, melanoma, Merkel cell carcinoma, mesothelioma, MSI-H CRC, NSCLC, ovarian cancer, SCCHN, SCLC, RCC, TNBC, or urothelial carcinoma.
    Note: A baseline biopsy obtained for other purposes (ie, not an INCAGN 1876-101 procedure) before signing consent may be used if the subject has not had any intervening systemic therapy from the time of the biopsy to the start of treatment (ie, Cycle 1 Day 1), and if a minimum of 20 slides or preferably 1 tissue block can be submitted. Note: Should not have received prior treatment with an immune therapy (eg, anti–CTLA-4, anti–PD-1, anti–PD-L1, IDO inhibitors, TNFSF agonists, or other antibodies or drugs specifically targeting T-cell costimulation or checkpoint pathways, etc).
    • Presence of measureable disease based on RECIST v1.1.
    • ECOG performance status 0 to 1.
    •Enfermedad metastásica o localmente avanzada; enfermedad localmente avanzada no debe ser susceptible de una resección con fines curativos.
    •Fase I: Sujetos con cáncer cuello uterino, endometrio, gástrico (incluidos cáncer estómago, esófago y UGE), CHC, melanoma( mucosal o cutaneo), carcinoma células de Merkel, mesotelioma, CCR IMS-A, CPNM, cáncer ovario, CECC, CMP, CCR, CMTN y carcinoma urotelial avanzados o metastásicos (Tipos de tumores alternativos con aprobación del monitor medico)
    •Fase I: Sujetos q muestren PE tras recibir ttos disponibles con beneficio clínico conocido, que no toleren el tto o rechacen el tto de ref. No existe limitación por número de regímenes terapéuticos previos.
    •Fase II: Sujetos con cáncer endometrio, gástrico (incluidos estómago, esófago y UGE) y CECC avanzados o metastásicos
    -Sujetos con cáncer endometrio: disponer del estado de la IMS documentado (ej.: IMS A, IMS baja, microsatélites estables) u otorgar consentimiento al centro correspondiente para realizar pruebas de IMS durante la selección. Nota: deberán haber recibido solo 1 régimen quimioterapéutico previo para enfermedad avanzada o metastásica (aparte de terapia neoadyuvante y/o adyuvante). Los regímenes adyuvantes administrados en plazo de 6 meses antes de la selección se considerarán ttos de 1ª línea. Nota: el tto previo no deberá haber incluido una inmunoterapia (ej.: frente al Ag 4 del linfocito T citotóxico [CTLA-4], la proteína 1 de muerte celular programada [PD 1], el ligando 1 de la proteína de muerte celular programada [PD-L1], con inhibidores de indolamina 2,3-dioxigenasa [IDO], agonistas de la superfamilia del factor de necrosis tumoral [TNFSF] u otros Ac o fármacos orientados a la coestimulación de los linfocitos T o de los ptos de control ...). Nota: podrán haber recibido previamente ttos hormonales o biológicos concomitante o como complemento de la quimioterapia sistémica previa.
    -Sujetos con cáncer gástrico: adenocarcinoma de estómago, esófago o UGE. Nota: deberán haber recibido únicamente 1régimen quimioterapéutico previo para la enfermedad avanzada o metastásica (aparte de la terapia neoadyuvante y/o adyuvante). Los regímenes adyuvantes administrados en un plazo de 6meses antes de la selección se considerarán ttos de 1ªlínea. Nota: el tto previo no deberá incluir una inmunoterapia (ej: anti-CTLA-4, anti-PD-1, anti-PD-L1, inhibidores de la IDO, agonistas de la TNFSF u otros anticuerpos o fármacos específicamente orientados a la coestimulación de los linfocitos T o los puntos de control, etc.). Nota: deberá conocerse el estado del HER-2/neu; sujetos con tumores + para HER2/neu deberán contar con la PE documentada durante o después del tto con trastuzumab u otros ttos que tengan a HER2/neu como diana
    -Sujetos con CECC: carcinoma epidermoide de cavidad oral, la orofaringe, la hipofaringe o la laringe confirmado mediante histología.Nota: sujetos con tumores adyacentes o que invadan vasos sanguíneos imp, si así se observa mediante pruebas de diagnóstico por imagen, no serán aptos para participar. Nota: deberán otorgar su consentimiento para evaluar el estado del VPH y el virus de Epstein-Barr (VEB) del tumor (disponibilidad en cada centro) o contar con pruebas documentadas del estado del VPH o el VEB.Nota: deberán haber recibido únicamente un régimen quimioterapéutico previo para la enfermedad avanzada o metastásica (aparte de la terapia neoadyuvante y/o adyuvante). Los regímenes adyuvantes administrados en un plazo de seis meses antes de la selección se considerarán ttos de 1ªlínea. La quimioterapia previa deberá contener platino. Nota: el tto previo no deberá incluir una inmunoterapia (ej.: anti-CTLA-4, anti-PD-1, anti-PD-L1, inhibidores de la IDO, agonistas de la TNFSF u otros anticuerpos o fármacos específicamente orientados a la coestimulación de los linfocitos T o los puntos de control ...).
    -Sujetos de la cohorte de biopsia: dispuestos a facilitar biopsias del tumor antes y durante el tto (con aguja gruesa o por escisión). Deben presentar cáncer cuello uterino, endometrio, gástrico (incluidos estómago, esófago y UGE), CHC, melanoma(mucoso o cutáneo), carcinoma células de Merkel, mesotelioma, CCR IMS-A, CPNM, cáncer ovario, CECC, CMP, CCR, CMTN o carcinoma urotelial.Nota: podrá usarse biopsia basal obtenida para otros fines (en el marco de un procedimiento ajeno al estudio INCAGN 1876-101) antes de firmar el consentimiento si el sujeto no se ha sometido a ningún tto sistémico intermedio entre realización de la biopsia e inicio del tto (ed, el día 1 del ciclo 1), y siempre que se disponga al menos de 20 cortes o preferiblemente un bloque de tejido. Nota: no deben haberse sometido a una inmunoterapia previa (ej.: anti-CTLA-4, anti-PD-1, anti-PD-L1, inhibidores de la IDO, agonistas TNFSF u otros Ac o fármacos orientados a coestimulación de linfocitos T o los puntos de control...).
    •Presencia de enfermedad medible en función de los criterios RECIST v1.1.
    •Estado funcional del ECOG de 0 a 1.
    E.4Principal exclusion criteria
    • Laboratory and medical history parameters not within the Protocol-defined range.
    − Absolute neutrophil count < 1.0 × 10^9/L
    − Platelets < 75 × 10^9/L
    − Hemoglobin < 9 g/dL or < 5.6 mmol/L
    − Serum creatinine > 1.5 × institutional upper limit of normal (ULN), OR measured or calculated creatinine clearance < 50 mL/min for subjects with creatinine levels > 1.5 × ULN.
    − Aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase ≥ 2.5 × ULN.
    − Total bilirubin ≥ 1.2 × ULN unless conjugated bilirubin ≤ ULN (conjugated bilirubin only needs to be tested if total bilirubin exceeds ULN). If there is no institutional ULN, then direct bilirubin must be < 40% of total bilirubin.
    − International normalized ratio, prothrombin time, or activated partial thromboplastin time > 1.5 × ULN.
    • Prior treatment with any TNFSF agonist (eg, glucocorticoid-induced tumor necrosis factor receptor [GITR], OX40, 4-1BB/CD137, CD27, etc), for any indication.
    • Transfusion of blood products (including platelets or red blood cells) or administration of colony stimulating factors within 14 days before study Day 1.
    • Receipt of anticancer medications or investigational drugs within the following intervals before the first administration of study drug:
    − ≤ 14 days for chemotherapy, targeted small molecule therapy, or radiation therapy. Note: Subjects must not have had radiation pneumonitis as a result of treatment. A 1-week washout is permitted for palliative radiation to non–central nervous system (CNS) disease with medical monitor approval. Note: Bisphosphonates and denosumab are permitted concomitant medications.
    − ≤ 28 days for prior immune therapy or persistence of active cellular therapy (ie, chimeric antigen receptor T-cell therapy; other cellular therapies must be discussed with medical monitor to determine eligibility).
    − ≤ 28 days for a prior monoclonal antibody used for anticancer therapy with the exception of denosumab.
    − ≤ 7 days for immune-suppressive–based treatment for any reason. Note: Use of inhaled or topical steroids or corticosteroid use for radiographic procedures is permitted. Note: Must not require chronic use of corticosteroids. The use of physiologic corticosteroid replacement therapy may be approved after consultation with the medical monitor.
    − ≤ 28 days or 5 half-lives (whichever is longer) before the first dose for all other investigational agents or devices. For investigational agents with long half-lives (eg, > 5 days), enrollment before the fifth half-life requires medical monitor approval.
    • Has not recovered to ≤ Grade 1 from toxic effects of prior therapy (including prior immune therapy) and/or complications from prior surgical intervention before starting therapy Note: Subjects with stable chronic conditions (≤ Grade 2) not expected to resolve (such as neuropathy and alopecia) are exceptions and may enroll. Note: Subjects with a history of any grade immune-related ocular AE (eg, episcleritis, scleritis, uveitis) will be excluded. Note: Subjects with a history of a Grade 3 or higher immune-related AE from prior immunotherapies are excluded from the dose escalation portion of the study.
    • Active autoimmune disease that required systemic treatment in the past (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Note: Subjects who have not required systemic treatment in the past 2 years should discuss their case with medical monitor to determine eligibility. Note: Subjects with hyper/hypothyroidism, vitiligo, controlled asthma, Type I diabetes, Graves' disease, or Hashimoto's disease are eligible to participate. Note: Replacement and symptomatic therapies (eg, levothyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc) are not considered a form of systemic treatment and are allowed.
    • Known active CNS metastases and/or carcinomatous meningitis. Note: Subjects with previously treated brain metastases may participate provided that they are stable (without evidence of progression by imaging for at least 28 days before the first dose of study drug and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases or CNS edema, and have not required steroids for at least 7 days before the first dose of study drug.
    • Evidence of active, noninfectious pneumonitis or history of interstitial lung disease.
    • History or presence of an abnormal electrocardiogram that, in the investigator's opinion, is clinically meaningful.
    • Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.
    • Known history of human immunodeficiency virus (HIV; HIV 1/2 antibodies).
    •P. analíticos o relativos al ht clínico fuera del intervalo def en protocol:
    Cifra abs de neutrófilos < 1,0 × 109/l.,Trombocitos <75 × 109/l.,Hemoglobina < 9 g/dl o < 5,6 mmol/l.,Creatinina sérica >1,5 veces el límite superior a la normalidad LNS del centro O aclaramiento creatinina det o calculado < 50 ml/min en sujetos con niveles de creatinina >1,5 veces el LSN.,Aspartato aminotransferasa, alanina aminotransferase y fosfatasa alcalina ≥2,5 veces el LSN,Se excluirán bilirrubina total ≥ 1,2 veces el LSN salvo q la bilirrubina conjugada sea ≤ el LSN (solo deberá analizarse la bilirrubina conjugada si la bilirrubina total supera el LSN). Si no existe un LSN del centro, la inclusión requiere valor de bilirrubina directa < 40% de la bilirrubina total,Índice internacional normalizado, tpo de protrombina o tpo de tromboplastina parcial activada >1,5 veces el LSN.
    •Tto previo con agonista de TNFSF (ej: R del factor de necrosis tumoral inducido por glucocorticoides [GITR], OX40, 4-1BB/CD137 y CD27, etc.) xa cualquier indicación.
    •Transfusión de hemoderivados (trombocitos o eritrocitos) o adm de facts estimulantes de colonias en plazo de 14 días antes del D 1 del estudio.
    •Recepción de mtos antineoplásicos o experimentales en intervalos antes de la adm de la 1ª dosis del fco del estudio:
    ≤ 14 días en quimioterapia, los ttos dirigidos con moléculas peq o la radioterapia.
    Nota: sujetos no podrán haber sufrido neumonitis por radiación como consecuencia del tto. Se permitirá 1 semana de reposo farmacológico xa radiación paliativa de 1 tumor q no afecte al SNC siempre q lo autorice el monitor médico.Nota: se permitirá la administración concomitante de bisfosfonatos y denosumab.
    ≤ 28 días en inmunoterapia previa o la persistencia de la terapia celular activa (ed linfocitos T con R de Ag quiméricos; la idoneidad de otras terapias cel deberá consultarse con el supervisor médico).
    ≤ 28 días en tto antineoplásico previo basado en Ac monoclonales, excepto denosumab.
    ≤ 7 días en ttos inmunodepresores x cualquier motivo.Nota: se permite uso de esteroides tópicos o inhalados o corticosteroides xa procedimientos radiográficos.Nota: no deben requerir uso crónico de corticoides. Podrá autorizarse uso de terapia de sustitución de la fx fisiológica con corticosteroides previa consulta al monitor médico.
    ≤ 28 días o 5 semividas (lo más largo) antes de la adm de 1ª dosis para el resto de fármacos o dispositivos experimentales. En fcos experimentales con una semivida larga (ej.: >5 días), la inclusión antes de la 5ª semivida precisará la autorización del monitor médico.
    •Efectos tóx de tto previo (incluida inmunoterapia previa) y/o complicaciones de intervención quirúrgica previa q no remitan a un grado ≤ 1 antes del inicio del tto.Nota:sujetos con afecciones crónicas estables (≤ grado 2)no previsto q se resuelvan (ej neuropatía y alopecia) se considerarán excepciones y no podrán ser incluidos.
    Nota: sujetos con antecedentes de AA oculares de cualquier grado relacionados con el sist inmune (ej: epiescleritis, escleritis, uveítis) quedarán excluidos.
    Nota:sujetos con antecedentes de AA relacionados con el sist inmune grado 3 o > como consecuencia de inmunoterapias previas quedarán excluidos de la etapa de aumento escalonado de la D del estudio.
    •Enfermedad autoinmunitaria activa q requiera tto sistémico en el pasado (ed, uso de fcos modificadores de la enfermedad, corticosteroides o fcos inmunodepresores).Nota: en sujetos que no hayan requerido tto sist en los últimos 2años, deberá consultarse con el monitor mco para det su idoneidad.Nota:sujetos con hiper/hipotiroidismo, vitíligo, asma controlado, diabetes de tipo I, la enfermedad de Graves-Basedow o la enf de Hashimoto: aptos para participar.Nota: ttos de reemplazo o sintomáticos (ej. levotiroxina, insulina o el tto de reemplazo fisiológico con corticosteroides de la insuf adenohipofisaria o suprarenal...) no se consideran una forma de tto sistémico: se permite su uso.
    •Metástasis en SNC activas conocidas y/o meningitis carcinomatosa.Nota: sujetos tratados previo por metástasis cerebrales podrán participar siempre q estén estables (sin evidencias de progresión en pruebas de diagnóstico por imagen en un plazo de al menos 28 días antes de la administración de 1ºdosis del fco en estudio y siempre que el síntoma neurológico haya remitido hasta valor basal), no presenten ningún indicio de metástasis cerebrales nuevas o en progresión ni edema del SNC y no hayan requerido uso de corticosteroides durante al menos 7 días antes de la administración de 1ªdosis del fármaco del estudio.
    •Indicios de neumonitis no infecciosa activa o antecedentes de neumopatía intersticial.
    •Antecedentes o presencia de anomalías en ECG que, en opinión del IP, sean significativas clinicamente.
    •Indicios de infección por virus hepatitis B o C o riesgo de reactivación de la enfermedad.
    •Antecedentes conocidos infección virus de la inmunodeficiencia humana (VIH; anticuerpos frente al VIH-1/VIH-2).
    E.5 End points
    E.5.1Primary end point(s)
    - Phase 1: Safety and tolerability (frequency, duration, and severity)
    - Phase 2: ORR, defined as the percentage of subjects having CR or PR, will be determined by investigator assessment of radiographic disease assessments per RECIST v1.1.
    Fase I: Seguridad, la tolerabilidad (frecuencia, duración e intensidad).
    Fase II: TRO, definida como el porcentaje de sujetos que muestren una respuesta completa (RC) o una respuesta parcial (RP), que se determinará mediante la valoración por parte del investigador de las evaluaciones radiográficas de la enfermedad en función de los criterios RECIST v1.1.
    E.5.1.1Timepoint(s) of evaluation of this end point
    up to end of study
    Hasta el final del estudio
    E.5.2Secondary end point(s)
    • ORR, defined as the percentage of subjects having CR or PR, will be determined by investigator assessment of radiographic disease assessments per RECIST v1.1 and mRECIST v1.1.
    • DOR, defined as the time from the earliest date of disease response (CR or PR) until earliest date of disease progression or death due to any cause, if occurring sooner than progression, will be determined by investigator assessment of radiographic disease assessment per RECIST v1.1 and mRECIST v1.1.
    • DCR, defined as the percentage of subjects having CR, PR, or stable disease (SD), will be determined by investigator assessment of radiographic disease assessments per RECIST v1.1 and mRECIST v1.1.
    • Duration of disease control (CR, PR, and SD) as measured from first report of SD or better until disease progression or death from any cause, if occurring sooner than progression, will be determined by investigator assessment of radiographic disease per RECIST v1.1 and mRECIST v1.1.
    • PFS, defined as the time from the start of combination therapy until the earliest date of disease progression or death due to any cause, if occurring sooner than progression, as determined by investigator assessment of objective radiographic disease assessments per RECIST v1.1 and mRECIST v1.1.
    • OS determined from the start of combination therapy until death due to any cause. Survival analyses will occur at 1-year, 2-years, and at the end of the study.
    • Safety and tolerability will be assessed by monitoring frequency, duration, and severity of AEs.
    •La TRO, definida como el porcentaje de sujetos que muestren una RC o una RP, que se determinará mediante la valoración por parte del investigador de las evaluaciones radiográficas de la enfermedad en función de los criterios RECIST v1.1 y mRECIST v1.1.
    •La duración de la respuesta, definida como el tiempo transcurrido desde la fecha más temprana de respuesta de la enfermedad (RC o RP) hasta la primera fecha de progresión de la enfermedad o la muerte por cualquier causa, si esta se produce antes que la progresión, que se determinará mediante la valoración por parte del investigador de las evaluaciones radiográficas de la enfermedad en función de los criterios RECIST v1.1 y mRECIST v1.1.
    •La TCE, definida como el porcentaje de sujetos que muestren una RC, una RP o enfermedad estable (EE), que se determinará mediante la valoración por parte del investigador de las evaluaciones radiográficas de la enfermedad en función de los criterios RECIST v1.1 y mRECIST v1.1.
    •Duración del control de la enfermedad (RC, RP y enfermedad estable [EE]), determinada desde la primera notificación de EE o una respuesta mejor hasta la progresión de la enfermedad, que se determinará mediante la valoración por parte del investigador de las evaluaciones radiográficas de la enfermedad en función de los criterios RECIST v1.1 y mRECIST v1.1 o hasta la muerte por cualquier causa si esta se produce antes que la progresión.
    •La SSP, definida como el tiempo transcurrido desde el inicio del tratamiento de combinación hasta la primera fecha de progresión de la enfermedad o la muerte por cualquier causa, si esta se produce antes que la progresión, determinada mediante la valoración por parte del investigador de las evaluaciones radiográficas de la enfermedad en función de los criterios RECIST v1.1 y mRECIST v1.1.
    •La SG, determinada desde el inicio del tratamiento de combinación hasta la muerte por cualquier causa. Los análisis de la supervivencia se realizarán al año, a los dos años y al final del estudio.
    •La seguridad y la tolerabilidad se evaluarán mediante el seguimiento de la frecuencia, la duración y la intensidad de los AA.
    E.5.2.1Timepoint(s) of evaluation of this end point
    up to end of study
    Hasta el final del estudio
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) Yes
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other Yes
    E.7.1.3.1Other trial type description
    Phase 1/2 study exploring safety, tolerability and efficacy
    Estudio de Fase 1/2 que estudia la seguridad, tolerabilidad y eficacia
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Information not present in EudraCT
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial7
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned10
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA23
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Belgium
    Italy
    Spain
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    ultima visita del ultimo paciente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months7
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 225
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 225
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state64
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 184
    F.4.2.2In the whole clinical trial 450
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None (Subjects may continue to receive study treatment as long as they are deriving benefit and have not met any of the protocol-defined conditions for treatment withdrawal)
    Ninguno (Los sujetos pueden seguir recibiendo tratamiento del estudio siempre y cuando obtengan beneficios y no hayan cumplido con ninguna de las condiciones definidas por el protocolo para el retiro del tratamiento)
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2017-09-28
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-09-08
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2021-11-09
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Sep 20 06:01:42 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA